slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 65,131-65,160
Pages 2,605
Rows per page 30
Component
65,131-65,160 of 78,138
17
Data presented at AASLD 2023; includes both a summary table and a longitudinal line chart with error bars.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
10
The slide uses a stacked bar/arrow hybrid to illustrate growth. The data points are 6,000 (US patients), 17,000 (RoW TAM), and 31,000 (US TAM).argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
11
The slide uses a two-stage framework to present clinical data and patient outcomes.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
18
Kaplan-Meier survival curve showing probability of being retreated with IVIg.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
25
The slide uses a bar chart to show growth and two tables for financial summaries.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
05
The right-hand side is a complex matrix mapping clinical trials to patient segments (HER2-positive, HR-positive, TNBC, gBRCAm) and treatment stages (Neoadjuvant, Adjuvant, Metastatic).AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Early StrugglesLoop · Logic Chain1 hit
16
The slide uses a waterfall-style growth diagram for Ultomiris and a combination of bar charts and bulleted metrics for HPP assets.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
04
The slide uses a Gantt-style visualization to show drug development progress across Preclinical, Phase 1, Phase 2, and Phase 3 stages.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
The slide cites a third-party study (Palhano-Fontes et al.) as proxy evidence for DMT efficacy.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide uses a line chart to show the change in MADRS scores over 12 weeks for three different dosages.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
18
The chart illustrates the pharmacokinetic advantage of IV delivery over oral administration.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The slide uses a line chart to show longitudinal changes in HCQ-29 subscales across three time points (Pre-dose, Discharge, 1 Month).ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
The slide uses a grouped bar chart to visualize T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage cohorts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
17
The slide uses a Gantt-style visualization to show the status of various drug development programs.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Loop · Golden Circle1 hit
08
The chart uses a Gantt-style visualization to show the progress of drug candidates through clinical phases.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
11
The chart uses a dot plot format to show the occurrence of specific GI symptoms over a 29-day study period across different subjects.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
12
The diagram illustrates a dose escalation study design with combination therapy.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
This is a classic 'spider plot' or 'swimmer plot' variant used in oncology clinical trials to visualize individual patient tumor burden changes over time.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The chart is a spider plot (or swimmer plot variant) showing change in target lesion size over time for individual patients.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
35
This is a classic swimmer plot used in oncology clinical trials to visualize time-on-treatment and response status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
40
The dashed box highlights the 'AXL low' expression group, showing significant anti-tumor activity.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
44
The chart is a waterfall plot showing percentage change in tumor size. Red bars indicate partial response (PR).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
52
The slide uses a before-after-bridge style framing to contrast the problem (toxicity in standard bispecifics) with the solution (BA3182).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
02
The slide uses stacked bar charts to compare AUM vs Base Fees for four different business segmentations.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations Beat · What Is1 hit
11
The chart uses a break in the Y-axis for the 2022 and 2023 bars.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations 1 hit
05
Includes a line chart showing Japanese visitor recovery relative to 2019 levels.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
09
The chart illustrates the bank's ability to maintain lower deposit costs than peers during interest rate cycles.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
12
Central Pacific Financial | Results Presentation Deck | 21 slidesCentral Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · Financials1 hit
14
The 4Q23 bar is split into 40.2 and 2.3, totaling 42.5. The asterisk denotes a one-time branch lease termination expense.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · Financials1 hit
17
Data as of December 31, 2023.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations 1 hit